Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias.

@article{Kohgo2015DeferasiroxDL,
  title={Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias.},
  author={Yutaka Kohgo and Akio Urabe and Yurdanur Kilinç and Leyla Ağaoğlu and Krzysztof Warzocha and Koichi Miyamura and Lay Cheng Lim and Sabine Glaser and Candace Wang and Wieslaw Wiktor-Jedrzejczak},
  journal={Acta haematologica},
  year={2015},
  volume={134 4},
  pages={233-42}
}
Iron overload in transfusion-dependent patients with rare anemias can be managed with chelation therapy. This study evaluated deferasirox efficacy and safety in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other rare anemias. A 1-year, open-label, multicenter, single-arm, phase II trial was performed with deferasirox (10–40 mg/kg/day, based on transfusion frequency and therapeutic goals), including an optional 1-year extension. The primary end point was a change in… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 33 references

48-month update on survival and AML transformation in a 600-patient registry of lower-risk MDS patients

RM Lyons, BJ Marek, +5 authors G Garcia-Manero
Blood • 2013

Estimation of the relationship between serum ferritin and liver iron concentration in patients with myelodysplastic syndromes

N Gattermann, P Greenberg, +3 authors J Porter
Haematologica • 2013

Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012

Similar Papers

Loading similar papers…